NASDAQ : EOLS
Evolus, Inc. — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 7.52 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 496.70M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 485.47M |
| Enterprise Value | 605.10M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 66.05M |
| Shares Outstanding | 66.05M |
| Shares Change (YoY) | +2.34% |
| Shares Change (QoQ) | +1.14% |
| Owned by Insiders (%) | 10.89% |
| Owned by Institutions (%) | 63.99% |
| Float | 49.77M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 172.94 |
| PS Ratio | 1.53 |
| Forward PS | 1.34 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 1.91 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.70 |
| Quick Ratio | 1.09 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.34 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -5.68% |
| Return on Invested Capital (ROIC) | -10.02% |
| Return on Capital Employed (ROCE) | -14.51% |
| Weighted Average Cost of Capital (WACC) | 10.64% |
| Revenue Per Employee | $896,567 |
| Profits Per Employee | -$97,261 |
| Employee Count | 353 |
| Asset Turnover | 1.33 |
| Inventory Turnover | 3.16 |
Taxes
| Measure | Value |
|---|
| Income Tax | 654,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.34 |
| 52-Week Price Change | +7.14% |
| 50-Day Moving Average | 7.98 |
| 200-Day Moving Average | 6.26 |
| Relative Strength Index (RSI) | 46.12 |
| Average Volume (20 Days) | 713,268 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 6.41M |
| Short Previous Month | 5.63M |
| Short % of Shares Out | 9.70% |
| Short % of Float | 12.88% |
| Short Ratio (days to cover) | 8.44 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 316.49M |
| Gross Profit | 210.16M |
| Operating Income | -21.66M |
| Pretax Income | -33.68M |
| Net Income | -34.33M |
| EBITDA | -12.77M |
| EBIT | -21.66M |
| Loss Per Share | -$0.53 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 45.17M |
| Total Debt | 164.80M |
| Net Cash | -119.63M |
| Net Cash Per Share | -$1.81 |
| Equity (Book Value) | -30.90M |
| Book Value Per Share | -0.47 |
| Working Capital | 68.81M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -15.38M |
| Capital Expenditures | -2.90M |
| Depreciation & Amortization | 8.89M |
| Net Borrowing | 9.98M |
| Free Cash Flow | -18.28M |
| FCF Per Share | -$0.28 |
Margins
| Measure | Value |
|---|
| Gross Margin | 66.40% |
| Operating Margin | -6.84% |
| Pretax Margin | -10.64% |
| Profit Margin | -10.85% |
| EBITDA Margin | -4.04% |
| EBIT Margin | -6.84% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.34% |
| Shareholder Yield | -2.34% |
| Earnings Yield | -7.17% |
| FCF Yield | -3.77% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $15.00 |
| Price Target Difference | 104.08% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 15.89% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -1.63 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |